T1	p 90 92	of
T2	p 128 187	patients with hemodynamically decompensated heart failure .
T3	p 282 311	decompensated cardiac failure
T4	p 427 448	human heart failure .
T5	p 540 582	16 decompensated heart failure patients in
T6	p 779 797	microgram/kg/min [
T7	p 960 984	group were excluded from
T8	p 1550 1558	patients
T9	p 1564 1573	resistant
T10	p 1958 1987	decompensated heart failure .
T11	i 29 42	neurohormonal
T12	i 233 239	hBNP )
T13	i 351 364	neurohormonal
T14	i 388 392	hBNP
T15	i 486 512	continuous 4-hour infusion
T16	i 516 520	hBNP
T17	i 625 643	placebo-controlled
T18	i 733 744	( placebo [
T19	i 760 773	hBNP 0.025 or
T20	i 779 795	microgram/kg/min
T21	i 928 934	hBNP .
T22	i 955 959	hBNP
T23	i 1026 1030	hBNP
T24	i 1092 1126	pulmonary capillary wedge pressure
T25	i 1323 1327	hBNP
T26	i 1425 1432	placebo
T27	i 1435 1439	hBNP
T28	i 1657 1661	hBNP
T29	i 1736 1740	hBNP
T30	i 1882 1885	. 4
T31	i 1888 1892	hBNP
T32	o 15 26	hemodynamic
T33	o 43 62	, and renal effects
T34	o 223 232	peptide (
T35	o 312 313	.
T36	o 328 348	systemic hemodynamic
T37	o 365 384	, and renal effects
T38	o 832 853	Urinary volume losses
T39	o 891 903	vasodilatory
T40	o 908 916	diuretic
T41	o 1017 1044	events . hBNP significantly
T42	o 1066 1087	right atrial pressure
T43	o 1092 1126	pulmonary capillary wedge pressure
T44	o 1175 1179	hBNP
T45	o 1207 1235	systemic vascular resistance
T46	o 1356 1369	cardiac index
T47	o 1397 1412	in heart rate .
T48	o 1435 1508	hBNP decreased plasma norepinephrine and aldosterone . Renal hemodynamics
T49	o 1593 1599	effect
T50	o 1634 1645	hemodynamic
T51	o 1681 1731	cardiac preload and systemic vascular resistance .
T52	o 1755 1769	cardiac output
T53	o 1789 1850	heart rate . 3 ) Plasma norepinephrine and aldosterone levels